Patents Assigned to Prelude Therapeutics Incorporated
  • CDK inhibitors and their use as pharmaceuticals
    Patent number: 11939340
    Abstract: The disclosure is directed to compounds of Formula I pharmaceutical compositions comprising compounds of Formula I, as well as methods of their use and preparation, are also described.
    Type: Grant
    Filed: January 20, 2023
    Date of Patent: March 26, 2024
    Assignee: Prelude Therapeutics Incorporated
    Inventors: Jincong Zhuo, Xiaowei Wu, Katarina Rohlfing, Andrew Combs
  • BRM targeting compounds and associated methods of use
    Patent number: 11702423
    Abstract: The present disclosure provides bifunctional compounds comprising a target protein binding moiety and a E3 ubiquitin ligase binding moiety, and associated methods of use.
    Type: Grant
    Filed: June 9, 2021
    Date of Patent: July 18, 2023
    Assignee: Prelude Therapeutics Incorporated
    Inventors: Hong Lin, Philip Pitis, Liang Lu, Andrew Paul Combs
  • SPIRO-SULFONIMIDAMIDE DERIVATIVES AS INHIBITORS OF MYELOID CELL LEUKEMIA-1 (MCL-1) PROTEIN
    Publication number: 20230212191
    Abstract: The disclosure is directed to compounds of Formula (I). Pharmaceutical compositions comprising compounds of Formula (I) as well as methods of their use and preparation, are also described.
    Type: Application
    Filed: April 16, 2021
    Publication date: July 6, 2023
    Applicant: PRELUDE THERAPEUTICS, INCORPORATED
    Inventors: Jincong ZHUO, Andrew Paul COMBS
  • CDK inhibitors and their use as pharmaceuticals
    Patent number: 11685744
    Abstract: The disclosure is directed to compounds of Formula I Pharmaceutical compositions comprising compounds of Formula I, as well as methods of their use and preparation, are also described.
    Type: Grant
    Filed: September 21, 2021
    Date of Patent: June 27, 2023
    Assignee: Prelude Therapeutics Incorporated
    Inventors: Andrew W. Buesking, Andrew Paul Combs, Jincong Zhuo, Ryan Holmes, Sarah Pawley, Xiaowei Wu
  • CDK inhibitors and their use as pharmaceuticals
    Patent number: 11673893
    Abstract: The disclosure is directed to, in part, to CDK inhibitors, pharmaceutical compositions comprising the same, as well as methods of their use and preparation.
    Type: Grant
    Filed: September 11, 2020
    Date of Patent: June 13, 2023
    Assignee: Prelude Therapeutics Incorporated
    Inventors: Liang Lu, Rupa Shetty, Andrew Paul Combs, Chaofeng Dai, Raul Andrew Leal, Klare Lazor Bersch
  • Substituted pyrrolo[2,3-d]pyrimidines as inhibitors of protein arginine methyl transferase 5 (PRMT5)
    Patent number: 11524962
    Abstract: The disclosure is directed to compounds of Formula (I) and Formula (II). Formula (I) and Formula (II) and pharmaceutically acceptable salts or solvates thereof. Pharmaceutical compositions comprising compounds of Formula (I) or Formula (II), as well as methods of their use and preparation, are also described.
    Type: Grant
    Filed: October 26, 2018
    Date of Patent: December 13, 2022
    Assignee: Prelude Therapeutics, Incorporated
    Inventors: Juan Luengo, Hong Lin, Michael Hawkins
  • Selective inhibitors of protein arginine methyltransferase 5 (PRMT5)
    Patent number: 11254683
    Abstract: The disclosure is directed to compounds of Formula I Pharmaceutical compositions comprising compounds of Formula I, as well as methods of their use and preparation, are also described.
    Type: Grant
    Filed: August 5, 2020
    Date of Patent: February 22, 2022
    Assignee: Prelude Therapeutics Incorporated
    Inventors: Juan Luengo, Hong Lin, Michael Hawkins, Rupa Shetty, Philip Pitis, Gisela Saborit Villarroya
  • Selective inhibitors of protein arginine methyltransferase 5 (PRMT5)
    Patent number: 11220524
    Abstract: The disclosure is directed to compounds of Formula I, Formula II, Formula III, Formula IV, Formula V, or Formula VI: Methods of their use in inhibiting a protein arginine methyltransferase 5 (PRMT5) enzyme and treating disease, as well as methods of their preparation are also described.
    Type: Grant
    Filed: February 20, 2018
    Date of Patent: January 11, 2022
    Assignee: Prelude Therapeutics Incorporated
    Inventors: Juan Luengo, Raul A. Leal, Hong Lin, Rupa Shetty, Krishna Vaddi
  • Selective inhibitors of protein arginine methyltransferase 5 (PRMT5)
    Patent number: 11214574
    Abstract: The disclosure is directed to compounds of Formula I Pharmaceutical compositions comprising compounds of Formula I, as well as methods of their use and preparation, are also described.
    Type: Grant
    Filed: June 1, 2020
    Date of Patent: January 4, 2022
    Assignee: Prelude Therapeutics, Incorporated
    Inventors: Juan Luengo, Hong Lin, Michael Hawkins, Rupa Shetty, Philip Pitis, Gisela Saborit Villarroya
  • Selective inhibitors of protein arginine methytransterase 5 (PRMT5)
    Patent number: 11208416
    Abstract: The disclosure is directed to compounds of Formula I Pharmaceutical compositions comprising compounds of Formula I, as well as methods of their use and preparation, are also described.
    Type: Grant
    Filed: August 5, 2020
    Date of Patent: December 28, 2021
    Assignee: Prelude Therapeutics Incorporated
    Inventors: Hong Lin, Juan Luengo, Rupa Shetty, Michael Hawkins
  • Spiro-sulfonamide derivatives as inhibitors of myeloid cell leukemia-1 (MCL-1) protein
    Patent number: 11130769
    Abstract: The disclosure is directed to compounds of Formula I Pharmaceutical compositions comprising compounds of Formula I as well as methods of their use and preparation, are also described.
    Type: Grant
    Filed: November 8, 2019
    Date of Patent: September 28, 2021
    Assignee: Prelude Therapeutics, Incorporated
    Inventors: Jincong Zhuo, Raul Leal, Rupa Shetty, Juan Luengo, Andrew Paul Combs, Peng Wei
  • Selective inhibitors of protein arginine methlytransferase 5 (PRMT5)
    Patent number: 11078205
    Abstract: The disclosure is directed to compounds of Formula I Pharmaceutical compositions comprising compounds of Formula I, as well as methods of their use and preparation, are also described.
    Type: Grant
    Filed: January 16, 2020
    Date of Patent: August 3, 2021
    Assignee: Prelude Therapeutics, Incorporated
    Inventors: Hong Lin, Juan Luengo, Rupa Shetty, Michael Hawkins
  • Selective inhibitors of protein arginine methyltransferase 5 (PRMT5)
    Patent number: 10711007
    Abstract: The disclosure is directed to compounds of Formula I Pharmaceutical compositions comprising compounds of Formula I, as well as methods of their use and preparation, are also described.
    Type: Grant
    Filed: April 5, 2019
    Date of Patent: July 14, 2020
    Assignee: Prelude Therapeutics Incorporated
    Inventors: Juan Luengo, Hong Lin, Michael Hawkins, Rupa Shetty, Philip Pitis, Gisela Saborit Villarroya
  • Selective inhibitors of protein arginine methyltransferase 5 (PRMT5)
    Patent number: 10570140
    Abstract: The disclosure is directed to compounds of Formula I Pharmaceutical compositions comprising compounds of Formula I, as well as methods of their use and preparation, are also described.
    Type: Grant
    Filed: August 9, 2018
    Date of Patent: February 25, 2020
    Assignee: Prelude Therapeutics Incorporated
    Inventors: Hong Lin, Juan Luengo, Rupa Shetty, Michael Hawkins